Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
88% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. MDXG: No Debt )
MDXG' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.81
MDXG's Equity to Asset is ranked higher than
86% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDXG: 0.81 )
MDXG' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.89
Current: 0.81

0.44
0.89
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
89% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. MDXG: No Debt )
MDXG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 35.35
M-Score: -2.43
WACC vs ROIC
17.49%
31.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 8.78
MDXG's Operating margin (%) is ranked higher than
81% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 5.14 vs. MDXG: 8.78 )
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98   Max: 6.01
Current: 8.78

-1334.98
6.01
Net-margin (%) 8.05
MDXG's Net-margin (%) is ranked higher than
83% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 3.47 vs. MDXG: 8.05 )
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4   Max: 5.26
Current: 8.05

-1447.4
5.26
ROE (%) 13.77
MDXG's ROE (%) is ranked higher than
88% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 4.76 vs. MDXG: 13.77 )
MDXG' s 10-Year ROE (%) Range
Min: -276.61   Max: 7.64
Current: 13.77

-276.61
7.64
ROA (%) 11.55
MDXG's ROA (%) is ranked higher than
93% of the 520 Companies
in the Global Medical Devices industry.

( Industry Median: 1.86 vs. MDXG: 11.55 )
MDXG' s 10-Year ROA (%) Range
Min: -557.14   Max: 6.41
Current: 11.55

-557.14
6.41
ROC (Joel Greenblatt) (%) 56.67
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 7.57 vs. MDXG: 56.67 )
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2458.54   Max: 39.25
Current: 56.67

-2458.54
39.25
Revenue Growth (3Y)(%) 111.50
MDXG's Revenue Growth (3Y)(%) is ranked higher than
100% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. MDXG: 111.50 )
MDXG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 293.6
Current: 111.5

0
293.6
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
Q3 2014

MDXG Guru Trades in Q3 2014

Joel Greenblatt 17,878 sh (New)
Jim Simons 251,000 sh (+39.52%)
Steven Cohen 825,000 sh (-9.02%)
» More
Q4 2014

MDXG Guru Trades in Q4 2014

Paul Tudor Jones 19,098 sh (New)
Joel Greenblatt 36,045 sh (+101.62%)
Steven Cohen Sold Out
Jim Simons 198,172 sh (-21.05%)
» More
Q1 2015

MDXG Guru Trades in Q1 2015

Steven Cohen 942,500 sh (New)
Paul Tudor Jones 38,800 sh (+103.16%)
Joel Greenblatt 61,414 sh (+70.38%)
Jim Simons 174,400 sh (-12.00%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 99.10
MDXG's P/E(ttm) is ranked higher than
75% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 99.10 )
MDXG' s 10-Year P/E(ttm) Range
Min: 89.61   Max: 1843.33
Current: 99.1

89.61
1843.33
Forward P/E 31.95
MDXG's Forward P/E is ranked higher than
83% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 31.95 )
N/A
PE(NRI) 102.10
MDXG's PE(NRI) is ranked higher than
77% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 102.10 )
MDXG' s 10-Year PE(NRI) Range
Min: 92.3   Max: 1106
Current: 102.1

92.3
1106
P/B 12.76
MDXG's P/B is ranked lower than
54% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 3.92 vs. MDXG: 12.76 )
MDXG' s 10-Year P/B Range
Min: 5.5   Max: 21.82
Current: 12.76

5.5
21.82
P/S 8.23
MDXG's P/S is ranked lower than
53% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 4.21 vs. MDXG: 8.23 )
MDXG' s 10-Year P/S Range
Min: 6.84   Max: 148
Current: 8.23

6.84
148
PFCF 68.07
MDXG's PFCF is ranked higher than
81% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 68.07 )
MDXG' s 10-Year PFCF Range
Min: 61.53   Max: 221.2
Current: 68.07

61.53
221.2
POCF 51.05
MDXG's POCF is ranked higher than
79% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 51.05 )
MDXG' s 10-Year POCF Range
Min: 46.15   Max: 372
Current: 51.05

46.15
372
EV-to-EBIT 86.98
MDXG's EV-to-EBIT is ranked higher than
75% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 259.85 vs. MDXG: 86.98 )
MDXG' s 10-Year EV-to-EBIT Range
Min: -299.1   Max: 1158.8
Current: 86.98

-299.1
1158.8
Current Ratio 4.46
MDXG's Current Ratio is ranked higher than
82% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. MDXG: 4.46 )
MDXG' s 10-Year Current Ratio Range
Min: 0.05   Max: 7.08
Current: 4.46

0.05
7.08
Quick Ratio 4.23
MDXG's Quick Ratio is ranked higher than
85% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. MDXG: 4.23 )
MDXG' s 10-Year Quick Ratio Range
Min: 0.05   Max: 6.7
Current: 4.23

0.05
6.7
Days Inventory 108.19
MDXG's Days Inventory is ranked higher than
82% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 172.71 vs. MDXG: 108.19 )
MDXG' s 10-Year Days Inventory Range
Min: 11.88   Max: 135.08
Current: 108.19

11.88
135.08
Days Sales Outstanding 81.15
MDXG's Days Sales Outstanding is ranked higher than
73% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 84.05 vs. MDXG: 81.15 )
MDXG' s 10-Year Days Sales Outstanding Range
Min: 74.94   Max: 103.26
Current: 81.15

74.94
103.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 44.39
MDXG's Price/Net Cash is ranked higher than
82% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 44.39 )
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43   Max: 140
Current: 44.39

20.43
140
Price/Net Current Asset Value 17.60
MDXG's Price/Net Current Asset Value is ranked higher than
75% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 17.60 )
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 11.35   Max: 147.5
Current: 17.6

11.35
147.5
Price/Tangible Book 15.47
MDXG's Price/Tangible Book is ranked higher than
54% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. MDXG: 15.47 )
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57   Max: 237.5
Current: 15.47

10.57
237.5
Price/DCF (Projected) 23.21
MDXG's Price/DCF (Projected) is ranked higher than
77% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 23.21 )
MDXG' s 10-Year Price/DCF (Projected) Range
Min: 23.64   Max: 354.5
Current: 23.21

23.64
354.5
Price/Median PS Value 0.70
MDXG's Price/Median PS Value is ranked higher than
93% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MDXG: 0.70 )
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 11.25
Current: 0.7

0.62
11.25
Price/Graham Number 8.24
MDXG's Price/Graham Number is ranked higher than
76% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 8.24 )
MDXG' s 10-Year Price/Graham Number Range
Min: 8.39   Max: 20.37
Current: 8.24

8.39
20.37
Earnings Yield (Greenblatt) 1.10
MDXG's Earnings Yield (Greenblatt) is ranked higher than
71% of the 505 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MDXG: 1.10 )
MDXG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.2
Current: 1.1

0.1
1.2

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
MiMedx To Present At The 12th Annual Craig-Hallum Institutional Investor Conference May 19 2015
MiMedx To Present At The 12th Annual Craig-Hallum Institutional Investor Conference May 19 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 15 2015
MiMedx Group upgraded by Northland Capital May 14 2015
MiMedx Announces Publication On CollaFix™, The Company's Next Technology Platform To Be... May 13 2015
Kite Pharma Inc (KITE), CoStar Group Inc (CSGP) And MiMedx Group Inc (MDXG): Top Stock Picks Of Len... May 11 2015
MiMedx Receives 2015 Innovative Technology Award from Novation May 08 2015
10-K for MiMedx Group, Inc. May 05 2015
10-Q for MiMedx Group, Inc. May 03 2015
MIMEDX GROUP, INC. Files SEC form 10-Q, Quarterly Report May 01 2015
Comparative Effectiveness Study Exhibiting Superior Outcomes Of MiMedx EpiFix® Receives Award At... Apr 29 2015
MiMedx Group Inc Earnings Call scheduled for 10:30 am ET today Apr 28 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 28 2015
Hynes Keller & Hernandez, LLC Announces Investigations of Trinity Industries, Inc., Vocera... Apr 28 2015
MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance Apr 27 2015
MiMedx To Present At The 40th Annual Deutsche Bank Securities Healthcare Conference Apr 23 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 14 2015
MiMedx Announces Expansion Of Health Plan Coverage Apr 14 2015
MiMedx Reports Record First Quarter 2015 Revenue of $40.8 Million Apr 13 2015
MiMedx Announces Expansion Of Health Plan Coverage Apr 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK